Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity

Annika Rössler; Janine Kimpel; Verena Fleischer; Silke Huber; Dorothee von Laer; Wegene Borena; Reinhard Würzner; HEVACC Study Group

doi:10.1093/infdis/jiac379

Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity

J Infect Dis. 2022 Nov 28;226(11):1909-1912. doi: 10.1093/infdis/jiac379.

Authors

Annika Rössler¹, Janine Kimpel¹, Verena Fleischer², Silke Huber², Dorothee von Laer¹, Wegene Borena¹, Reinhard Würzner²; HEVACC Study Group

Collaborators

HEVACC Study Group:
David Bante, Barbara Falkensammer, Helena Schäfer, Florian Krammer, Peter Pichler, Ursula Wiedermann, Daniel Rainer, Tobias Trips, August Zabernigg

Affiliations

¹ Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.
² Institute of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Innsbruck, Austria.

Abstract

We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2.

Keywords: SARS-CoV-2; antibody kinetics; avidity; heterologous vaccination.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenoviridae
Antibody Affinity*
BNT162 Vaccine* / immunology
COVID-19* / prevention & control
ChAdOx1 nCoV-19* / immunology
Humans
Kinetics
Spike Glycoprotein, Coronavirus / genetics
Vaccination

Substances

BNT162 Vaccine
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
ChAdOx1 nCoV-19

Grants and funding

HOROS W-1253/FWF_/Austrian Science Fund FWF/Austria